Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

safimaltib (JNJ-6633)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

J&J

Drug class:

MALT1 protein inhibitor

Related drugs:

‹

›

CARD11 mutation	Diffuse Large B Cell Lymphoma	CARD11 mutation	Diffuse Large B Cell Lymphoma	JNJ-6633 Sensitive: D – Preclinical JNJ-6633 Sensitive : D	JNJ-6633 Sensitive: D – Preclinical JNJ-6633 Sensitive : D
CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	JNJ-6633 Sensitive: D – Preclinical JNJ-6633 Sensitive : D	JNJ-6633 Sensitive: D – Preclinical JNJ-6633 Sensitive : D
CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	JNJ-6633 + JNJ-4681 Sensitive: D – Preclinical JNJ-6633 + JNJ-4681 Sensitive : D	JNJ-6633 + JNJ-4681 Sensitive: D – Preclinical JNJ-6633 + JNJ-4681 Sensitive : D